We need to use gene editing wisely but also embrace its vast potential
By Mary Warnock,
The Guardian
| 03. 11. 2018
The Royal Society has recently published the results of an extensive survey of the attitudes of the general public to genetic modification. This sent my mind back to 1990, when the human fertilisation and embryology bill was going through parliament.
The emphasis, at least in the House of Lords, where the bill started, very soon switched from remedies for infertility to the new concept of eliminating some heritable diseases. IVF could be used to select embryos in the laboratory that did not carry the disease and implant one or two of those in the mother’s uterus. At the time, it was also speculated that one day it might be possible to eliminate a faulty gene from a live embryo after a pregnancy had been established, rather than at the pre-implantation stage.
I remember being astonished by how little this had to do with infertility, which was, after all, in the title of the bill, and what the committee I chaired had been set up to consider.
It came about almost entirely because of the enthusiasm of a then newly...
Related Articles
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
Alice Wong, founder of the Disability Visibility Project, MacArthur Genius, liberationist, storyteller, writer, and friend of CGS, died on November 14. Alice shone a bright light on pervasive ableism in our society. She articulated how people with disabilities are limited not by an inability to do things but by systemic segregation and discrimination, the de-prioritization of accessibility, and the devaluation of their lives.
We at CGS learned so much from Alice about disability justice, which goes beyond rights...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...